Gardos G, Cole J O, Rapkin R M, LaBrie R A, Baquelod E, Moore P, Sovner R, Doyle J
Arch Gen Psychiatry. 1984 Nov;41(11):1030-5. doi: 10.1001/archpsyc.1983.01790220020003.
Benztropine mesylate (intravenous [IV] and oral) challenge was compared with brief neuroleptic withdrawal on dyskinesia ratings and symptom measures. Thirty-six neuroleptic-treated patients underwent a placebo-controlled acute IV challenge with 2 mg benztropine and a placebo-controlled two-week trial of oral benztropine mesylate (2 mg three times a day), followed by a double-blind placebo-controlled neuroleptic withdrawal involving four weeks of dose tapering and six weeks of placebo treatment. Benztropine given IV had no significant effect. Orally administered benztropine, however, led to statistically significant increases in dyskinesia and dysphoric mood. The brief neuroleptic withdrawal significantly increased dyskinesia scores and dysphoria and resulted in early termination of therapy in 12 of 36 patients (33%) due to symptom exacerbation. There was a striking absence of correlation between dyskinesia change measures brought about by benztropine and changes following neuroleptic withdrawal. Therefore anticholinergic challenge does not appear to be a fruitful procedure for identifying patients with covert dyskinesia.
将甲磺酸苯扎托品（静脉注射和口服）激发试验与短暂停用抗精神病药物在运动障碍评分和症状测量方面进行了比较。36名接受抗精神病药物治疗的患者接受了2毫克甲磺酸苯扎托品的安慰剂对照急性静脉注射激发试验以及甲磺酸苯扎托品（每日3次，每次2毫克）的安慰剂对照为期两周的口服试验，随后是双盲安慰剂对照的抗精神病药物撤药试验，包括四周的剂量递减和六周的安慰剂治疗。静脉注射苯扎托品没有显著效果。然而，口服苯扎托品导致运动障碍和烦躁情绪在统计学上显著增加。短暂停用抗精神病药物显著提高了运动障碍评分和烦躁情绪，并且由于症状加重，36名患者中有12名（33%）提前终止了治疗。苯扎托品引起的运动障碍变化测量与抗精神病药物撤药后的变化之间明显缺乏相关性。因此，抗胆碱能激发试验似乎不是识别隐匿性运动障碍患者的有效方法。
